BioNTech SE (BNTX)
BioNTech SE, engages in the development and commercialization of immunotherapies in Germany.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
BioNTech is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- It carries less debt and has more breathing room than most other healthcare companies.
- Worth watching
- Its growth over the past year trails most other healthcare companies.
Analyst price target
~12-month · 20 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus…
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7,807
- Headquarters
- Mainz, Germany
Similar stocks
What’s behind the score
Valuation
P/B 1.1 — lower than 100% of Healthcare peers
P/S 8.3 — lower than 17% of Healthcare peers
EV/EBITDA -6.4 — lower than 97% of Healthcare peers
EV/Revenue 3.4 — lower than 70% of Healthcare peers
PEG 0.1 — lower than 100% of Healthcare peers
FCF yield -1.1% — higher than 0% of Healthcare peers
Profitability & quality
Gross margin 76.6% — higher than 87% of Healthcare peers
Operating margin -806.6% — higher than 0% of Healthcare peers
Net margin -63.6% — higher than 3% of Healthcare peers
ROE -9.3% — higher than 7% of Healthcare peers
ROA -5.4% — higher than 3% of Healthcare peers
Financial health
Debt/equity 0.0 — lower than 100% of Healthcare peers
Current ratio 7.85 — higher than 100% of Healthcare peers
Quick ratio 7.03 — higher than 100% of Healthcare peers
Cash/debt 42.59 — higher than 100% of Healthcare peers
Debt/EBITDA -0.23 — lower than 100% of Healthcare peers
Growth
Revenue growth -59.5% YoY — higher than 0% of Healthcare peers
Ownership & investor activity
Payout ratio 0.0% — somewhat unusual vs Healthcare peers
Institutions net sold, -11.9% of shares held
Insiders hold 57.2% of shares outstanding
3.7% of float sold short
Momentum
Below its 50- & 200-day averages
18% of the way from its 52-week low to high